
Overview
Background
Dr. Wenyi Gu’s early education was conducted in China which include his undergraduate and master’s degrees in veterinary medicine. In 1996, he migrated to Australia and pursued his PhD study in biochemistry & molecular biology at the Australian National University (ANU). After a short period of work at John Curtin Medical School ANU as a junior scientist, he moved to Brisbane in 2001 for his post-doc at the University of Queensland and currently a post-doctoral research fellow at AIBN. He held a Peter Doherty Fellowship (2006-2009) and was further supported by NHMRC to spend 7 months at Harvard University as a visiting fellow in 2008. Since his post-doctoral research he has been working in the area of using RNAi to treat viral diseases and cancers. He also has a strong background in immunology and vaccine development.
Availability
- Dr Wenyi Gu is:
- Available for supervision
Fields of research
Qualifications
- Doctor of Philosophy, Australian National University
Research interests
-
Rational design and delivery of small RNAs for effective cancer gene therapies
Major research focus is on RNA interference (RNAi) based gene therapy and cancer therapy. Closely associated with this focus, research areas such as oncogenes, cancer stem cells, targeted delivery systems, cancer cell biomarkers, and cancer immunotherapy are also covered. My recent research is more concentrated on RNAi delivery with nano-particles and on identifying therapeutic targets for cancer stem cells and exploring novel therapeutic approaches including using small RNAs or chemotherapeutic drugs or nature compounds to inhibit cancer stem cell growth.
Research impacts
Dr. Gu's research focus is on RNA interference (RNAi) based gene therapy and cancer therapy. Closely associated with this focus, he also interests in subjects such as oncogenes, cancer stem cells, targeted delivery, cancer cell biomarkers, and cancer immunotherapy. His recent research more focuses on RNAi delivery with nano-particles and on identifying therapeutic targets for cancer stem cells and exploring novel therapeutic approaches to inhibit cancer stem cell growth. His discovery that RNAi induces immunity to tumour antigens has led to a whole new field of biomedical research – that is the relationship between RNAi and acquired immune responses, and the role of RNAi techniques as specific and effective vaccine development tools for cancers and other diseases. This discovery has not only underpinned a high quality publication in PNAS USA but also an international patent that has been licensed by the world’s largest RNAi company, Alnylam Pharmaceuticals USA. Building on this, his recent research confirms that RNAi therapy has a profound effect on cancer stem cells (Gu et al 2011). More recently, he worked with his colleagues on RNAi therapy on osteoarthritis, which led to a high quality paper published by Nature Communication.
Works
Search Professor Wenyi Gu’s works on UQ eSpace
2011
Journal Article
Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs
Gu, Wenyi, Payne, Elizabeth, Sun, Surong, Burgess, Melinda and McMillan, Nigel A. J. (2011). Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs. Cancer Gene Therapy, 18 (3), 219-227. doi: 10.1038/cgt.2010.72
2010
Journal Article
Expression of papillomavirus L1 proteins regulated by authentic gene codon usage is favoured in G2/M-like cells in differentiating keratinocytes
Ding, Jianmin, Doorbar, John, Li, Bo, Zhou, Fang, Gu, Wenyi, Zhao, Liang, Saunders, Nicholas A., Frazer, Ian H. and Zhao, Kong-Nan (2010). Expression of papillomavirus L1 proteins regulated by authentic gene codon usage is favoured in G2/M-like cells in differentiating keratinocytes. Virology, 399 (1), 46-58. doi: 10.1016/j.virol.2009.12.021
2009
Conference Publication
RNA interference for the treatment of cervical cancers: Solving the delivery and efficacy issues
Gu, W. Y., Leggatt, G., Payne, E., Wilson, D., Choyce, A. and McMillan, N. A. J. (2009). RNA interference for the treatment of cervical cancers: Solving the delivery and efficacy issues. 6th Meeting of the Australasian Gene Therapy Society, Sydney, Australia, 29 April - 01 May 2009. Hoboken, NJ, United States: John Wiley & Sons. doi: 10.1002/jgm.1375
2008
Journal Article
siRNA and shRNA as anticancer agents in a cervical cancer model
Gu, Wenyi, Putral, Lisa and McMillan, Nigel (2008). siRNA and shRNA as anticancer agents in a cervical cancer model. Methods in Molecular Biology, 442, 159-172. doi: 10.1007/978-1-59745-191-8_12
2008
Book Chapter
siRNA and shRNA as anti-cancer agents in a cervical cancer model
Gu, W., Putral, L. and McMillan, N. A. J. (2008). siRNA and shRNA as anti-cancer agents in a cervical cancer model. RNAi : design and application. (pp. 159-172) edited by J. M. Walker. Totowa, N.J., U.S.A.: Humana Press, Inc..
2007
Journal Article
Calcium enhances mouse keratinocyte differentiation in vitro to differentially regulate expression of papillomavirus authentic and codon modified L1 genes
Fang, N. X., Gu, W., Ding, J., Saunders, N. A., Frazer, I. H. and Zhao, K. N. (2007). Calcium enhances mouse keratinocyte differentiation in vitro to differentially regulate expression of papillomavirus authentic and codon modified L1 genes. Virology, 365 (1), 187-197. doi: 10.1016/j.virol.2007.03.038
2007
Journal Article
The development and future of oligonucleotide-based therapies for cervical cancer
Gu, W. Y., Putral, L. N., Irving, A. and McMillan, N. A. J. (2007). The development and future of oligonucleotide-based therapies for cervical cancer. Current Opinions in Molecular Therapeutics, 9 (2), 126-131.
2007
Journal Article
Future of RNAi-based therapies for human papillomavirus-associated cervical cancer
Irving, A, McMillan, N and Gu, WY (2007). Future of RNAi-based therapies for human papillomavirus-associated cervical cancer. Future Virology, 2 (6), 587-595. doi: 10.2217/17460794.2.6.587
2006
Journal Article
Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes
Gu, W., Putral, L., Hengst, K., Minto, K., Saunders, N. A., Leggatt, G. and McMillan, N. A. J. (2006). Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Therapy, 13 (11), 1023-1032. doi: 10.1038/sj.cgt.7700971
2006
Journal Article
RNA interference for the treatment of cancer
Putral, Lisa N., Gu, Wenyi and McMillan, Nigel A. J. (2006). RNA interference for the treatment of cancer. Drug News & Perspectives, 19 (6), 317-324. doi: 10.1358/dnp.2006.19.6.985937
2005
Journal Article
Lymphocytes and MHC class II positive cells in the female rabbit reproductive tract before and after ovulation
Gu, Wenyi, Janssens, Peter, Holland, Michael, Seamark, Robert and Kerr, Peter (2005). Lymphocytes and MHC class II positive cells in the female rabbit reproductive tract before and after ovulation. Immunology and Cell Biology, 83 (6), 596-606. doi: 10.1111/j.1440-1711.2005.01375.x
2005
Journal Article
Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo
Zhao, Kong-Nan, Gu, WenYi, Fang, Ning Xia, Saunders, Nicholas A. and Frazer, Ian H. (2005). Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo. Molecular And Cellular Biology, 25 (19), 8643-8655. doi: 10.1128/MCB.25.19.8643-8655.2005
2005
Journal Article
RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin
Putral, L. N., Bywater, M. J., Gu, W. Y., Saunders, N. A., Gabrielli, B. G., Leggatt, G. R. and McMillan, N. A. J. (2005). RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Molecular Pharmacology, 68 (5), 1311-1319. doi: 10.1124/mol.105.014191
2004
Journal Article
Increased mononuclear cell activation and apoptosis early after human liver transplantation is associated with a reduced frequency of acute rejection
Jonsson, Julie R., Gu, Wenyi, Vanags, Daina M., Bishop, G. Alex, McCaughan, Geoffrey W., Fawcett, Jonathon, Lynch, Stephen V., Balderson, Glenda A., Powell, Elizabeth E. and Clouston, Andrew D. (2004). Increased mononuclear cell activation and apoptosis early after human liver transplantation is associated with a reduced frequency of acute rejection. Liver Transplantation, 10 (3), 397-403. doi: 10.1002/lt.20084
2004
Journal Article
Immune response in rabbit ovaries following infection of a recombinant myxoma virus expressing rabbit zona pellucida protein B
Gu, Wenyi, Holland, Michael, Janssens, Peter, Seamark, Robert and Kerr, Peter (2004). Immune response in rabbit ovaries following infection of a recombinant myxoma virus expressing rabbit zona pellucida protein B. Virology, 318 (2), 516-523. doi: 10.1016/j.virol.2003.10.021
2004
Journal Article
tRNASer(CGA) differentially regulates expression of wild-type and codon-modified papillomavirus L1 genes
Gu, Wenyi, Li, Mengrong, Zhao, Wei Ming, Fang, Ning Xia, Bu, Shurui, Frazer, Ian H. and Zhao, Kong-Nan (2004). tRNASer(CGA) differentially regulates expression of wild-type and codon-modified papillomavirus L1 genes. Nucleic Acids Research, 32 (15), 4448-4461. doi: 10.1093/nar/gkh748
2003
Journal Article
Effects of additional sequences directly downstream from the AUG on the expression of GFP gene
Zhao, Kong-Nan, Tomlinson, Liz, Liu, Wen Jun, Gu, Wenyi and Frazer, Ian H. (2003). Effects of additional sequences directly downstream from the AUG on the expression of GFP gene. BBA - Biochimeca et Biophysica Acta: international journal of biochemistry and biophysics, 1630 (2-3), 84-95. doi: 10.1016/j.bbaexp.2003.09.010
2003
Journal Article
Antibody response in the female rabbit reproductive tract to influenza haemagglutinin encoded by a recombinant myxoma virus
Gu, Wenyi, Holland, Michael, Janssens, Peter and Kerr, Peter (2003). Antibody response in the female rabbit reproductive tract to influenza haemagglutinin encoded by a recombinant myxoma virus. Virology, 313 (1), 286-295. doi: 10.1016/S0042-6822(03)00324-6
2003
Conference Publication
Absence of rejection after human liver orthotopic liver transplantation (OLT) is associated with leukocyte apoptosis, increased lymphocyte activation and higher donor cell chimerism
Clouston, A., Vanags, D. M., Gu, W. Y., Powell, E. E. and Jonsson, J. R. (2003). Absence of rejection after human liver orthotopic liver transplantation (OLT) is associated with leukocyte apoptosis, increased lymphocyte activation and higher donor cell chimerism. 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease, Boston, MA, United States, 24-28 October 2003. Hoboken, NJ, United States: John Wiley & Sons.
Funding
Supervision
Availability
- Dr Wenyi Gu is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Available projects
-
Identifying therapeutic targets and developing targeted cancer therapies for cancer stem cells
-
Drug delivery with nanotechnology and RNA interference based thearpy
Supervision history
Current supervision
-
Doctor Philosophy
Roles of surface expression of PD-L1 and the regulation by E2 in human endometrial and breast cancers
Associate Advisor
-
Doctor Philosophy
Translational meaning of the efficacy of immunotherapies as neoadjuvants to treat Head and Neck cancers.
Associate Advisor
Other advisors: Dr Merja Joensuu, Professor Michael Monteiro
-
Doctor Philosophy
Roles of surface expression of PD-L1 and the regulation by E2 in human endometrial and breast cancers
Associate Advisor
Completed supervision
-
2022
Doctor Philosophy
Development of Nanoparticle Platforms for Targeted Delivery and Enhanced Immunity of DNA Vaccines Against Tumour Antigens
Principal Advisor
-
2021
Doctor Philosophy
Development of lipid-coated calcium phosphate (LCP) nanoparticles as albendazole carrier for cancer therapy
Associate Advisor
-
2021
Doctor Philosophy
Targeting hypoxic cancer stem cells with nanoparticles
Associate Advisor
Other advisors: Professor Andrew Whittaker, Dr Cheng Zhang, Associate Professor Barbara Rolfe
-
2020
Doctor Philosophy
Developing inorganic nanoplatforms for efficient siRNA delivery to improve cancer immunotherapy
Associate Advisor
-
2019
Doctor Philosophy
Developing lipid-coated calcium carbonate/phosphate hybrid nanoparticles as a gene/drug co-delivery platform for combined cancer therapy
Associate Advisor
-
2018
Doctor Philosophy
Developing layered double hydroxides into multi-functional vehicles for efficient anti-tumour vaccination
Associate Advisor
Other advisors: Associate Professor Barbara Rolfe
-
2016
Doctor Philosophy
Contribution of complement anaphylatoxin receptors to melanoma growth: potential therapeutic targets
Associate Advisor
Other advisors: Professor Trent Woodruff, Associate Professor Barbara Rolfe
-
2015
Doctor Philosophy
Bio-inspired Virus-mimicking Nanoparticles for Efficient Cellular Delivery
Associate Advisor
Other advisors: Professor Michael Yu
-
2014
Doctor Philosophy
Designed synthesis of mono-dispersed silica-based nanostructures and their applications in drug/gene delivery
Associate Advisor
Other advisors: Professor Michael Yu
-
2014
Doctor Philosophy
Designer Mesoporous Silica Nano-carriers for Hydrophobic Drug Delivery with Enhanced Bioavailability
Associate Advisor
Other advisors: Professor Michael Yu
-
2014
Doctor Philosophy
A Novel Platform Built on Designed Materials for Purification, Enrichment and Detection of Bio-Molecules
Associate Advisor
Other advisors: Professor Michael Monteiro, Professor Michael Yu
-
2014
Doctor Philosophy
The role of complement anaphylatoxin receptors in mammary tumour growth: identification of new therapeutic targets
Associate Advisor
Other advisors: Professor Trent Woodruff, Associate Professor Barbara Rolfe
-
2011
Doctor Philosophy
RNAi against Virally-Induced Disease
Associate Advisor
Other advisors: Associate Professor Graham Leggatt
Media
Enquiries
For media enquiries about Dr Wenyi Gu's areas of expertise, story ideas and help finding experts, contact our Media team: